WallStSmart

PetMed Express Inc (PETS)vsScienture Holdings, Inc. (SCNX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

PetMed Express Inc generates 20459% more annual revenue ($168.86M vs $821,320). SCNX leads profitability with a 0.0% profit margin vs -17.3%. PETS earns a higher WallStSmart Score of 43/100 (D).

PETS

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.3Quality: 5.0
Piotroski: 2/9Altman Z: 1.29

SCNX

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 0.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PETSUndervalued (+70.8%)

Margin of Safety

+70.8%

Fair Value

$10.16

Current Price

$1.65

$8.51 discount

UndervaluedFair: $10.16Overvalued
SCNXUndervalued (+61.0%)

Margin of Safety

+61.0%

Fair Value

$1.15

Current Price

$0.35

$0.80 discount

UndervaluedFair: $1.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PETS3 strengths · Avg: 9.3/10
EPS GrowthGrowth
266.7%10/10

Earnings expanding 266.7% YoY

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

SCNX3 strengths · Avg: 9.7/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
449.1%10/10

Revenue surging 449.1% year-over-year

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

Areas to Watch

PETS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.324/10

Expensive relative to growth rate

Market CapQuality
$39.24M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-100.6%2/10

ROE of -100.6% — below average capital efficiency

SCNX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.32M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : PETS

The strongest argument for PETS centers on EPS Growth, Debt/Equity, Price/Book.

Bull Case : SCNX

The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.

Bear Case : PETS

The primary concerns for PETS are PEG Ratio, Market Cap, Piotroski F-Score.

Bear Case : SCNX

The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

PETS profiles as a turnaround stock while SCNX is a hypergrowth play — different risk/reward profiles.

SCNX carries more volatility with a beta of 3.98 — expect wider price swings.

SCNX is growing revenue faster at 449.1% — sustainability is the question.

SCNX generates stronger free cash flow (-3M), providing more financial flexibility.

Bottom Line

PETS scores higher overall (43/100 vs 33/100). SCNX offers better value entry with a 61.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

PetMed Express Inc

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

PetMed Express, Inc., doing business as 1-800-PetMeds, is a pet pharmacy in the United States. The company is headquartered in Delray Beach, Florida.

Scienture Holdings, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as the demand for effective neurological therapies continues to rise.

Want to dig deeper into these stocks?